Shots:
- The companies entered into an exclusive research agreement for the discovery of novel small molecules targeting α-synuclein for the potential treatment of synucleinopathies including PD and dementia with Lewy bodies
- The collaboration will use Wren’s network kinetics drug discovery platform along with Eisai’s experience in drug discovery for neurodegenerative disorders, to accelerate the development of clinical candidates
- The agreement focuses on developing a disease-modifying treatment for synucleinopathies based on network kinetics of α-synuclein misfolding and aggregation
Click here to read full press release/ article | Ref: Businesswire | Image: Betahaus I Berlin
The post Eisai Sign a Research Agreement with Wren Therapeutics to Discover Potential Treatment for Synucleinopathies first appeared on PharmaShots.
